Anemia as associated with numerous clinical conditions can be debilitating, but frequently can be treated via administration of epoetin-alfa, darbepoietin-alfa or methoxy-PEG epoetin-beta. Despite the complexity of EPO-EPO receptor interactions, the development of interesting EPO mimetic peptides (EMPs) also has been possible. CNTO 
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INTRODUCTION
As recombinant injectables, epoetin-alfa and darbepoietin-alfa are important therapeutics for anemia 1, 2 .
Via its canonical dimeric single-transmembrane receptor (EPOR) 3, 4 , and possibly a hypothesized accessory chain 5, 6 , erythropoietin (EPO) also has been shown to confer significant cytoprotection for certain injured non-hematopoietic tissues 7 . This includes renal, cardiac, brain and retinal cells as damaged by ischemia, neurotoxins or UV irradiation [8] [9] [10] [11] . However, epoetin-alfa can require frequent injections in anemia contexts, as well as relatively high dosing to cytoprotect non-hematopoietic cells 7 .
To address these issues, several EPO-related erythropoiesis stimulating agents (ESAs) recently have been formulated and shown to possess one, or another, advantaged property. One orthologue is darbepoietin-alfa in which non-essential residues are mutated to provide for two additional N-linked glycosylation sites 13 . This can enhance darbepoietin-alfa's in vivo half-life 14 , and EPO receptor occupancy 15 . Together, these properties can lessen dosing frequency 14 . A second example is provided by "Epo-Epo" in which EPO is configured as a peptide linked head-to-tail dimer 16 . For EpoEpo, unique properties include enhanced secretion, and apparent advantaged in vivo activity following subcutaneous injection 17 . In addition, a pegylated epoetin-beta has been developed (CERA) that possesses a significantly extended half-life 18 , and likewise can be effectively utilized with less frequent dosing 19 .
A distinct approach to preparing ESAs involves the development of monoclonal antibodies which can bind, and activate the EPOR. In particular, Liu et al. 20 recently described ABT007 as one such agent, and via crystallographic analyses provided evidence for unique EPOR domain interactions. In an alternate approach, initial success has also been indicated for small molecule ESAs in the form of HIF prolyl hydroxylase inhibitors 21 . As activated by hypoxia, HIFs (hypoxia inducible factors) act as heterodimeric HIF-ARNT PAS-domain transcription factors to promote the expression of several hypoxia response genes including Epo 22 . HIF degradation is regulated, in part, via prolyl hydroxylation 21 .
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In a third unique approach to ESA development, Jolliffe and coworkers 23, 24 previously applied phage display technologies to discover EPO mimetic peptides (EMPs) which despite a lack of sequence homology to EPO, bind and biologically stimulate the EPOR. Crystallographic analyses have revealed structural details of EMP1 -EPOR binding, and provided direct evidence for EPOR's occurrence as a homodimeric receptor 3, 4 . In monomeric form, EMP activity in vivo, however, is limited 25 .
Presently, we have characterized the activities of a unique ESA, CNTO 530, which is constructed as a dimeric EMP fused to a human lgG4 Fc scaffold. Analyses in murine models first reveal uniquely high and sustained erythropoietic activity for CNTO 530 as compared to epoetin-alfa, and darbepoietin-alfa.
CNTO 530's erythropoietic effects also were exhibited via advantaged amelioration of the anemia induced by 5-fluorouracil, or carboplatin plus paclitaxel. In ex vivo analyses using primary bone marrow erythroblasts, several common phosphoprotein signal transduction factors and target response genes were defined for CNTO 530 and epoetin-alfa. However, CNTO 530 more strongly and persistently stimulated p70S6K. In vivo, CNTO 530 uniquely enforced the enhanced formation of PODXL high CD71 high erythroblasts, as well as the sustained expansion of a Kit neg CD71 high Ter119 neg erythroid progenitor pool in bone marrow at levels several-fold above epoetin-alfa or darbepoietin-alfa. CNTO 530 therefore represents a highly effective ESA whose actions interestingly appear to depend, in part, on its unique engagement of the EPOR, together with the persistent stimulation of a defined cohort of targeted proerythroblasts.
MATERIALS AND METHODS
Mouse and rat models -For all in vivo and ex vivo analyses, mice used were strain C57BL/6 at age 8-12 weeks. Epoetin-alfa (EPO) (Eprex®alfa) (Ortho Biotech, Raritan, NJ), darbepoietin-alfa Hematological analyses -For peripheral blood samples, hematocrits, hemoglobin levels, and reticulocyte frequencies were determined using an Advia 120 hematology analyzer (Siemens Medical Solutions Diagnostics, Tarrytown, NY). Hematocrits and reticulocytes also were assayed independently via microcapillary centrifugation, and flow cytometry as described previously 28 . For personal use only. on . by guest www.bloodjournal.org From mg/mL phenylmethylsulfonylfluoride, 1x protease inhibitor and 1x phosphatase inhibitor cocktails (Sigma). 1% Triton-X 100, 0.5% sodium deoxycholate, 0.1% SDS, 112.5 mM NaCl, 37.5 mM Tris-HCL (pH 7.4) then was added (0.15 mL). Cleared extracts were assayed for protein content, denatured, electrophoresed and blotted. Antibodies used were phospho-p70S6K and p70S6K (Cell Signaling, Danvers, MA, #9204 and # 9202), phospho-AKT and AKT (Cell Signaling #9271 and #9272); phospho-STAT5 and STAT5 (Cell Signaling #9351 and #9352); and phospho-ERK1,2 and ERK1,2 (Cell Signaling #9106 and #9102). In chemiluminescence, HRP-conjugated antibodies (Jackson Immunoresearch, West Grove, PA) and Super-Signal West-Dura reagent (Pierce Biotechnology, Rockford, IL) were used.
Primary erythroblast preparations -
Signals were analyzed quantitatively using Image-J software (http://rsb.info.nih.gov/ij/).
RESULTS

Erythropoietic properties of CNTO 530 in steady-state and anemia models
To advance a characterization of CNTO 530's in vivo biological properties, basic dose-response studies first were performed. Primary analyses were in adult mice at steady-state, and included comparisons to both epoetin-alfa (EPO), and darbepoietin-alfa. Specifically, erythropoietic activity was examined based on increases in hematocrits following dosing with CNTO 530, darbepoietin-alfa or epoetin-alfa. CNTO 530 and darbepoietin-alfa were as single doses. Epoetin-alfa was administered at 1 and 24 hours (to compensate for epoetin-alfa's shorter half-life) 14, 29 . Analyses revealed an ability of CNTO 530 to persistently increase hematocrits by day 8 to >15 points ( Figure 1A ). This differed from response profiles for epoetin-alfa and darbepoietin-alfa in which increases in hematocrits peaked at somewhat lower levels at day 4, and subsequently decreased by day 8. to 48 hours for darbepoietin-alfa 31, 32 ; and 6 to 24 hours for epoetin-alfa 29, 33 ).
Given CNTO 530's capacity to promote erythropoiesis in a sustained fashion, its performance in 5-fluorouracil (5FU) and paclitaxel plus carboplatin induced anemia models next was assessed ( Figure 2 ).
In 5-FU experiments, mice received 150 mg/kg, and were then dosed with either CNTO 530 or darbepoietin-alfa at day 4.5 at doses of 0.3 ug / g-rat and 0.02 ug / g-rat, respectively. 5-FU-induced anemia proved to be lessened in severity by CNTO 530 (e.g., by 7.5 hematocrit points at day 15.5), but not significantly so by darbepoietin-alfa ( Figure 2A ).
For personal use only. on . by guest www.bloodjournal.org From Next, in paclitaxel plus carboplatin experiments, rats were dosed with these chemotherapuetic agents on days 1, 8 and 15. On day 16 (a point at which hematocrits fell to approximately 25%) (see below), CNTO 530 or darbepoietin-alfa was administered, each at two doses as 1.0 and 3.0 ug / g-rat (CNTO 530) or 0.03 and 0.3 ug / g-rat (darbepoietin-alfa). By day 28, both darbepoietin-alfa and CNTO 530 provided > 5 g/dL advantage in hemoglobin levels ( Figure 2B upper panel) . At day 35, 42 and 56, however, CNTO 530 when dosed at 3.0 ug/ g-mouse uniquely continued to provide marked advantages in hemoglobin levels. As analyzed in parallel, 5 to >10 point advantages in hematocrits also were realized at these time points due to CNTO 530 dosing ( Figure 2B lower panel) . Therefore, anemia in this model was selectively lessened by high-dose CNTO 530.
CNTO 530 stimulation of signal transduction pathways in primary bone marrow erythroblasts
Based on CNTO 530's potent erythropoietic activities, and unique configuration as an IgG4 Fc-fused homodimeric EMP, analyses next focused on CNTO 530-stimulated signal transduction events in primary proerythroblasts. Via an initial basic analysis, the abilities of CNTO 530 vs epoetin-alfa to support bone marrow CFUe formation first were compared. Specifically, low doses of each ESA required for essentially matched sub-maximal CFUe stimulation first were defined (i.e., 0.08 U/mL EPO and 0.08 μ g/ml CNTO 530. Activities of these and equivalent fold-increased doses of each ESA then were assessed. Interestingly, as doses increased, CNTO 530 more readily stimulated the formation of [8] [9] [10] [11] [12] [13] [14] [15] [16] cell CFUe colonies ( Figure 3A ).
In subsequent signal transduction experiments, primary bone marrow-derived erythroblasts were used which were isolated as a highly EPO μ g/mL transferrin, 0.1 mM 2-ME, 10 μ g/mL insulin in IMDM.
Proerythroblasts then were exposed to either CNTO 530 (0.5 μ g/mL) or epoetin-alfa (2U/mL). At 0, 10, 20, 40 and 80 minutes, lysates were prepared and analyzed by western blotting for phospho-activation of the above signal transduction factors (Figure 3 B-D) . For P-S473-AKT, P-Y694-STAT5, and P-T202/Y204-ERK1,2, CNTO 530-stimulated activation profiles largely paralleled those generated by epoetin-alfa (Figure 3 B-D) . For p70S6K, however, its activation by CNTO 530 at late time points interestingly persisted as compared directly to EPO. To confirm this interesting result, adjusted doses of CNTO 530 and EPO were defined that stimulated p70S6K T421/S424 phosphorylation at comparable levels. Blots were then probed for ERK1,2 T202/Y204 phosphorylation levels. These analyses of a coprocessed and ECL-developed blot again confirmed differentials, here, with comparably decreased ERK1,2 activation for CNTO 530 relative to p70S6K (see supplemental Figure S-1 Previously, epoetin-alfa has been demonstrated to stimulate a rapid release of reticulocytes from marrow into peripheral blood 36 . We therefore first examined effects of epoetin-alfa and CNTO 530 on this possible response in two-hour time-frame experiments. Epoetin-alfa proved to stimulate a significant efflux of reticulocytes to blood at two hours to levels that were approximately 180% over levels elicited by CNTO 530 ( Figure 4A ). This provoked the notion that late-stage nucleated erythroid progenitor cells also might be affected, and this was studied by co-staining for DRAQ5 positivity among CD71 high peripheral blood cells (again at a two hour interval). Notably, a significant efflux of these progenitors also was observed in response to epoetin-alfa, but again was lesser in response to CNTO 530 (with epoetin-alfainduced levels 238% over CNTO 530) ( Figure 4B ). Results therefore are consistent with the notion that epoetin-alfa, more than CNTO 530, may rapidly stimulate an emptying of a late pool of red cell progenitors from marrow.
Effects of CNTO 530 on erythropoiesis within bone marrow per se next were analyzed, and further were compared directly to epoetin-alfa and darbepoietin-alfa. To limit effects due to differing half-lives, epoetin-alfa was administered at both 1 and 24 hours at a dose (2U /g-mouse) which by day 4 supported reticulocyte (and red blood cell) formation at levels highly similar to those afforded by CNTO 530 (at 0 Figure 6B ). At day 2.5 post ESA dosing, darbepoietin-alfa and CNTO 530 each markedly modulated stage-E2 cell frequencies, with 10-and 13-fold increases realized, respectively. E1 progenitor pools remained low, and were comparably unaffected ( Figure 6C, left panel) . Perhaps most strikingly, at day 4.5 post ESA administration, the expansion of stage-E2 progenitor cells proved to be sustained uniquely in response to CNTO 530 ( Figure 6C, right panel) 
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DISCUSSION
For CNTO 530, several unique properties and apparently distinct action modes, presently are defined that merit discussion. These include, first, CNTO 530's notable erythropoietic activity as demonstrated at steady-state and within two chemotherapeutic agent-induced anemia models. Second, CNTO 530's capacities to activate known EPO/EPOR signal transduction pathways are defined, together with several distinguishing signaling effects. Finally, a third property of significant interest involves CNTO 530's unique in vivo abilities to enhance the formation of Podocalyxin -positive erythroid progenitors, and to also promote the sustained expansion of a defined (pro)erythroblast pool within bone marrow.
In basic concentration-dependent, and time-course experiments, CNTO 530 efficiently promoted red cell production for up to 25 days following a single injection at sub-maximum dosing (see Figure 1 ). This amplification of the adult erythron was more robust than that provided by epoetin-alfa or darbepoietinalfa. In part, this may reflect differential half-lives which for CNTO 530 recently has been shown to approximate 40 hours 30 . By day 10, however, >95% of CNTO 530 is predicted to become unavailable.
This therefore points to additional mechanistic explanations for CNTO 530's potency (see below). Here, it also should be considered that on a molar basis, an approximate ten-fold higher mass of CNTO 530 over epoetin-alfa is required to achieve maximal bioactivity. This may reflect properties involved with marrow entry, potential EPOR on-and/or off-rates, and/or other as yet undefined features. As an IgG4 Fc fusion protein, CNTO 530 is readily prepared and purified. Requirements for higher mass dosing therefore are not disadvantageous. In its single dose format, CNTO 530 also proved to be uniquely advantageous in limiting the anemia induced by 5-fluorouracil, or paclitaxel plus carboplatin. In particular, and at essentially matched doses, CNTO 530 but not darbepoietin was observed to lessen the severity of anemia incurred following 5-FU mediated myelo-depletion (see Figure 2A ). In the case of an optimized paclitaxel/carboplatin model, however, anemia was not so much affected at these doses by either darbepoietin or CNTO 530. When doses were increased to approximately 10-fold over maximal steadystate doses, however, CNTO 530 (but not darbepoietin-alfa) interestingly was capable of significantly For personal use only. on . by guest www.bloodjournal.org From lessening this anemia in severity and duration (see Figure 2B ). Why this dosing difference exists between effects in a 5FU (mouse) model vs paclitaxel/carboplatin (rat) model presently is unclear.
Nonetheless, the unique ameliorating effects of CNTO 530 in each model are apparent. In future studies, it will be of significant interest to establish CNTO 530's effectiveness in additional geneticallybased anemia models (eg, thalassemia and/or sickle cell). Phase I clinical trials for CNTO 530 likewise indicate initially promising erythropoietic effects 37 .
In initial characterizations of CNTO 530's molecular action modes, 30 , we demonstrated this EMP's ability to competitively bind to the EPOR, and to stimulate the growth and survival of an EPO-dependent cell line, UT7epo 30, 38 . Presently, we have used primary bone marrow derived Kit 39, 40 . However, p70S6K activation also can be regulated by PDK1,2 41 ; PKC 42 ; PP2A and PTP1b phosphatases 43, 44 , and ubiquitination 45 . Which pathway might be engaged by CNTO 530 to sustain S6K activation is presently undefined, but is of significant interest. Functionally, S6K can exert diverse effects on cell growth, development, homeostasis and protein translation 46 , and therefore comprises an interesting effector for future investigations of CNTO 530's action mechanisms. With regards to ERK1,2 increased activation via a PY-mutated EPOR-HM allele interestingly has been observed and has been functionally linked to perturbed proerythroblast differentiation events 47 . How interactions of this homodimeric EPO mimetic peptide with the EPOR might differentially sustain this response also is of interest, especially in the context of a conformation-mediated model for the activation of dimeric EPOR plus JAK2 complexes 48 .
For
high erythroid bone marrow progenitor cells. This was obvious as early as day-2 postdosing, and subsequently was reinforced at days 4 and 6 (see Figure 5C ). At day 6, this effect of CNTO 530 on PODXL pos progenitors expansion in marrow, in fact, was realized at levels six-fold beyond those promoted by either epoetin-alfa or darbepoietin-alfa. Using primary bone marrow erythroblasts and a global profiling approach, we recently discovered Podxl as a major EPO response gene 27 . PODXL is a transmembrane sialomucin and CD34 orthologue 49 . In renal podocytes, PODXL is thought to function in maintaining diaphragm slits 50 . In contrast, in hematopoietic stem cells 26 and potentially in certain cancers (e.g. prostate and certain leukemias) 51, 52 , PODXL may act as an adhesion and /or cell migration factor. It therefore might be speculated through correlation that PODXL, as persistently induced by CNTO 530 may affect the residency of erythroid progenitors in marrow.
A second effect as discovered via extended analyses of Kit 
